Clinical Trials · NCT04166773
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 190
- Start date
- Nov 2019
- Locations
- 112 sites, 10 countries
- Primary endpoint
- Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology